Connect Biopharm

Company snapshot

Connect Biopharm is a biotech organization headquartered in CN. Primary therapeutic focus areas include Autoimmune Diseases. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 1 (1).

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Connect Biopharm. Not investment advice.

• What is Connect Biopharm?

  Connect Biopharm is a biotech organization headquartered in CN. Primary therapeutic focus areas include Autoimmune Diseases. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO so

• Is Connect Biopharm publicly traded?

  Connect Biopharm appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Connect Biopharm develop or market?

  No drug profiles are currently linked to Connect Biopharm. Pipeline programs may still list investigational assets.

• What are the latest developments for Connect Biopharm?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Connect Biopharm focus on?

  Connect Biopharm focuses on Autoimmune Diseases based on our analysis of their pipeline programs and drug development activities.